FindTrial
Sign In

vitamin D and calcium Supplementation reduces the complication of letrozole in breast cancer patients

A study on the effects of vitamin D and calcium Supplementation on side effects profile in patients of breast Cancer treated with letrozole

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/07/002792
Enrollment
150
Registered
2012-07-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Postmenopausal breast cancer patients

Interventions

Intervention1: Tab Letrozole,Tab Vitamin D3,Tab Calcium No placebo group: Tab Letrozole 2.5mg per day is given orally to all patients in the study. In patient with vitamin D level less than 10ng/ml-

Sponsors

Instititional fundJawaharlal Institute Of Post Graduate Medical Education And Research Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Postmenopausal Estrogen receptor positive breast cancer patients receiving Letrozole for more than 2 months

Exclusion criteria

Exclusion criteria: Patients with bone metastasis, History of renal stones, Serum calcium greater than 11mg/dl, Patients with renal failure, Patients taking steroid hormone replacement.

Design outcomes

Primary

MeasureTime frame
Decrease of Letrozole side effects & improvement in the musculoskeletal symptoms.Timepoint: within 3 months—

Secondary

MeasureTime frame
improvement in the musculoskeletal symptomsTimepoint: within 3 months—

Countries

India

Contacts

Public ContactArul Vijaya Vani S

JIPMER

phananthanarayanan@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026